TheraStel Labs LLC is a biotechnology startup developing a new class of cancer therapeutics based on the control of tumor bioelectric signaling. The company integrates ion-channel–targeted therapeutic candidates with a proprietary localized drug delivery system designed to improve treatment of aggressive and therapy-resistant cancers. TheraStel Labs originated from research conducted by Saverio Gentile, Ph.D and Davide Delisi, Ph.D and focuses on translating discoveries in ion-channel pharmacology and tumor bioelectric regulation into clinically actionable therapies.